Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 603 All time
- Disclosed funding
- $28.7B 480 disclosed amounts
- Median round
- $17M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
Allos AICompany profile Causal AI and pharmaceutical development services for reformulating complex drugs and directing laboratory studies. Causal AI and pharmaceutical development services for reformulating complex drugs and directing laboratory studies. | $5M | Seed | Biotech, AI | United States | Investors | |
| TB Trailhead BiosystemsCompany profile Develops human cells with defined molecular and functional properties for drug discovery and regenerative medicine Develops human cells with defined molecular and functional properties for drug discovery and regenerative medicine | $20M | Growth | Biotech | United States | Investors | |
| OT Oricell TherapeuticsCompany profile Develops next-generation cell therapies for oncology and immunology Develops next-generation cell therapies for oncology and immunology | $70M | Series C1Series C+ | Biotech | China | Investors | |
| JT Develops regenerative biologics to restore tissue function | $33.5M | Series B | Biotech | United States | Investors | |
| O Develops AI-based predictive genomics approach to target discovery | £2.5M | Seed | Biotech | United Kingdom | Investors | |
| KT Develops inhaled therapies for severe respiratory diseases | $103M | Series B | Biotech | United States | Investors | |
MEDIPOSTCompany profile MEDIPOST develops stem-cell therapies derived from donated umbilical cord blood. MEDIPOST develops stem-cell therapies derived from donated umbilical cord blood. | $140M | Undisclosed | Biotech | United States | Investors | |
| b bit.bioCompany profile Creates functional, human-relevant cells and models for research, drug discovery, and development Creates functional, human-relevant cells and models for research, drug discovery, and development | $50M | Series CSeries C+ | Biotech | United Kingdom | Investors | |
AirNexis TherapeuticsCompany profile AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01. AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01. | $200M | Series A | Biotech | United States | Investors | |
| V Builds technologies for spatial biology and multi-omics innovation | $48M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Delix Therapeutics, Alethio Therapeutics, Estuary Biotherapeutics
27rounds6led - 2Eli Lilly and Company
Oyster Therapeutics, BigHat Biosciences, Circle Pharma, Inc.
16rounds0led - 3Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
16rounds1led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
16rounds1led - 5OrbiMed
Dren Bio, Star Therapeutics, Leal Therapeutics
12rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.